Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Cervical CancerUterine Cancer
Interventions
DRUG

Bevacizumab

10 mg/kg IV twice weekly on days 1 and 15.

DRUG

Paclitaxel

60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00626561 - Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix | Biotech Hunter | Biotech Hunter